Cinctive Capital Management LP Has $3.71 Million Position in Encompass Health Co. (NYSE:EHC)

Cinctive Capital Management LP raised its position in Encompass Health Co. (NYSE:EHC - Free Report) by 33.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,381 shares of the company's stock after purchasing an additional 9,626 shares during the quarter. Cinctive Capital Management LP's holdings in Encompass Health were worth $3,709,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. UMB Bank n.a. grew its position in Encompass Health by 387.7% in the third quarter. UMB Bank n.a. now owns 317 shares of the company's stock worth $31,000 after acquiring an additional 252 shares in the last quarter. V Square Quantitative Management LLC lifted its position in shares of Encompass Health by 53.0% in the third quarter. V Square Quantitative Management LLC now owns 404 shares of the company's stock worth $39,000 after buying an additional 140 shares during the last quarter. Oakworth Capital Inc. acquired a new position in shares of Encompass Health during the 2nd quarter valued at about $40,000. Avior Wealth Management LLC bought a new position in shares of Encompass Health in the third quarter valued at approximately $40,000. Finally, Benjamin F. Edwards & Company Inc. lifted its position in Encompass Health by 58.9% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 534 shares of the company's stock worth $46,000 after acquiring an additional 198 shares during the last quarter. 97.25% of the stock is owned by hedge funds and other institutional investors.

Encompass Health Price Performance

Shares of EHC traded down $0.26 on Tuesday, hitting $102.14. The company's stock had a trading volume of 186,615 shares, compared to its average volume of 637,726. The company has a 50 day moving average price of $98.16 and a 200 day moving average price of $91.45. Encompass Health Co. has a fifty-two week low of $64.15 and a fifty-two week high of $104.55. The company has a market capitalization of $10.29 billion, a PE ratio of 24.73, a PEG ratio of 1.36 and a beta of 0.86. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.04 and a quick ratio of 1.04.

Encompass Health (NYSE:EHC - Get Free Report) last released its quarterly earnings results on Monday, October 28th. The company reported $1.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.94 by $0.09. The business had revenue of $1.35 billion during the quarter, compared to analysts' expectations of $1.33 billion. Encompass Health had a return on equity of 17.60% and a net margin of 8.10%. The firm's revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.86 earnings per share. On average, research analysts anticipate that Encompass Health Co. will post 4.29 earnings per share for the current fiscal year.

Encompass Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Thursday, January 2nd will be paid a dividend of $0.17 per share. The ex-dividend date of this dividend is Thursday, January 2nd. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.67%. Encompass Health's dividend payout ratio (DPR) is presently 16.43%.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on EHC. Truist Financial reiterated a "buy" rating and set a $116.00 price target (up from $108.00) on shares of Encompass Health in a report on Wednesday, October 30th. KeyCorp raised their price target on shares of Encompass Health from $115.00 to $117.00 and gave the stock an "overweight" rating in a research report on Tuesday, October 29th. Barclays increased their target price on shares of Encompass Health from $109.00 to $116.00 and gave the company an "overweight" rating in a research note on Tuesday, October 29th. Royal Bank of Canada boosted their price target on Encompass Health from $105.00 to $110.00 and gave the company an "outperform" rating in a research note on Wednesday, October 30th. Finally, UBS Group lifted their price objective on Encompass Health from $100.00 to $110.00 and gave the stock a "buy" rating in a report on Wednesday, September 25th. Nine research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Encompass Health currently has an average rating of "Buy" and an average price target of $107.11.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.